A Phase 3 interventional study of EN3409 in Low Back Pain, Osteoarthritis and Neuropathic Pain, sponsored by BioDelivery Sciences International. Completed at 57 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-18.
Sponsored by BioDelivery Sciences International · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 712 studies in Low Back Pain with a site in United States — 100 open to participants now, 126 under way, 3 of them phase 3. Low Back Pain · United States.
Among the 712 studies in Low Back Pain with a site in United States, this one is the 84th largest by enrollment of the 623 interventional ones that give a count, is one of 31 that started in 2012, is one of 62 in phase 3, and was the 226th registered.
2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.
Browse Low Back Pain studies →100 of the 712 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 18+
New York Medical College · Sites in United States
Ages 18+
Loma Linda University · Sites in United States
Ages 18–65 · Healthy volunteers
University of Central Florida · Sites in United States
Ages 18–65
Eli Lilly and Company · Sites in United States, Puerto Rico
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
712 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 35 · Phase 2 80 · Phase 3 73 · Phase 4 50
First in 1977; this study’s year is marked. 31 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 304 is above the median of 60 across 2,369 interventional studies indexed under Low Back Pain.
Median enrollment 79 across the 623 interventional studies, 90 across the 85 observational. Of the 513 that completed or were terminated, 207 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
156 of 712 have an industry lead sponsor. The 10 most frequent:
BioDelivery Sciences International is the lead sponsor of 21 studies on the registry; 1 is open to participants now.
BioDelivery Sciences International has 6 studies filed under Low Back Pain — fewer than ten, so there is no comparison to draw.
52 of the studies in Low Back Pain with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07254806Phase 3DiscGenics, Inc.A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease | 2027-11-24 |
| NCT07125027National University of Natural MedicineA Multicomponent Intervention for Patients With Lumbosacral Radiculopathy: Move-MORE | 2026-11 |
| NCT07652944Joe X. ZhangTrial to Test the Efficacy of Using Magnetic Fields to Stimulate the Back to Treat Chronic Lower Back Pain. | 2026-11 |
| NCT04730700University of Kansas Medical CenterEvaluation of Multi-Tined Expandable Electrode (MEE) Efficacy and Safety in Treatment of Lumbar Facet Arthropathy by Radiofrequency Neurotomies Compared to Conservative Medical Management. | 2026-11-30 |
| NCT06007976Mayo ClinicLLLT to Reduce Low Back Pain | 2026-12 |
Add all 52 to your calendar (.ics) → With an account.
Among the 712 studies in Low Back Pain with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the long-terms study is to evaluate the safety, tolerability, and analgesic efficacy of EN3409 in subjects with moderate to severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Buprenorphine HCI Buccal File at doses ranging from 300-900 mcg twice daily
Drug: EN3409
Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily
Also known as: Buprenorphine HCI Buccal Film 300-900 mcg twice daily
Change From Baseline to Week 48 in Daily Average NRS Pain Intensity Score
The NRS Pain intensity score is a segmented version of a visual analog scale used to measure pain. The scale is from 0 (no pain) to 10. Scores between greater than 0 and 3 are considered mild pain, scores from greater than 3 to 6 are moderate and greater than 6 to 10 are severe. The daily average is calculated and the change from baseline at week 48 is presented.
Time frame: 48 weeks
| Milestone | Overall |
|---|---|
| Started | 304 |
| Completed | 294 |
| Not completed | 10 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Any other reason and screen failures | 5 |
| Milestone | Overall |
|---|---|
| Started | 294 |
| Completed | 224 |
| Not completed | 70 |
| Withdrew: Adverse event | 11 |
| Withdrew: Lack of efficacy | 18 |
| Withdrew: Protocol violation | 9 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Other and continuing | 22 |
| Withdrew: Withdrawal by subject | 8 |
| Milestone | Overall |
|---|---|
| Started | 224 |
| Completed | 103 |
| Not completed | 121 |
| Withdrew: Adverse event | 12 |
| Withdrew: Lack of efficacy | 6 |
| Withdrew: Protocol violation | 10 |
| Withdrew: Withdrawal by subject | 35 |
| Withdrew: Lost to follow-up | 17 |
| Withdrew: Other and ongoing | 41 |
The NRS Pain intensity score is a segmented version of a visual analog scale used to measure pain. The scale is from 0 (no pain) to 10. Scores between greater than 0 and 3 are considered mild pain, scores from greater than 3 to 6 are moderate and greater than 6 to 10 are severe. The daily average is calculated and the change from baseline at week 48 is presented.
| units on a scale | Overall |
|---|---|
| Change From Baseline to Week 48 in Daily Average NRS Pain Intensity Score | 0.2 ± 1.78 |
Collected over 48 Weeks. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Overall | — | 12/224 (5.4%) | 115/224 (51.3%) |
| Event | Overall |
|---|---|
| BronchitisInfections and infestations | 1/224 |
| CellulitisInfections and infestations | 1/224 |
| SepsisInfections and infestations | 1/224 |
| UrosepsisInfections and infestations | 1/224 |
| SyncopeNervous system disorders | 1/224 |
| Status migrainosusNervous system disorders | 1/224 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/224 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/224 |
| NephrolithiasisRenal and urinary disorders | 1/224 |
| Renal impairmentRenal and urinary disorders | 1/224 |
| Event | Overall |
|---|---|
| NauseaGastrointestinal disorders | 18/224 |
| Upper respiratory tract infectionInfections and infestations | 14/224 |
| Back painMusculoskeletal and connective tissue disorders | 13/224 |
| HeadacheNervous system disorders | 12/224 |
| VomitingGastrointestinal disorders | 11/224 |
| DiarrheaGastrointestinal disorders | 10/224 |
| BronchitisInfections and infestations | 9/224 |
| ConstipationGastrointestinal disorders | 9/224 |
| DepressionPsychiatric disorders | 8/224 |
| NasopharyngitisInfections and infestations | 7/224 |
Baseline at start of Long-Term Treatment Phase
| Age, Categorical(Participants) | Overall |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 193 |
| >=65 years | 31 |
| Age, Continuous(Years) | Overall |
|---|---|
| Mean | 52 ± 11.80 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 125 |
| Male | 99 |
| Ethnicity (NIH/OMB)(Participants) | Overall |
|---|---|
| Hispanic or Latino | 39 |
| Not Hispanic or Latino | 185 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall |
|---|---|
| American Indian or Alaska Native | 3 |
| Asian | 6 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 57 |
| White | 158 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Weight (kg)(kilograms) | Overall |
|---|---|
| Mean | 92.2 ± 21.57 |
| Height (cm)(centimeters) | Overall |
|---|---|
| Mean | 169.5 ± 10.39 |
| BMI (kg/m^2)(kg/m^2) | Overall |
|---|---|
| Mean | 32.1 ± 7.20 |
2 further baseline measures are reported on the registry.
The record gives a start of Dec 2012, a primary completion of Oct 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2018, 3 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
BioDelivery Sciences International